What are the ICON‑7 (International Collaborative Ovarian Neoplasm) and GOG‑218 (Gynecologic Oncology Group‑218) regimens for advanced ovarian cancer, including their chemotherapy components and bevacizumab dosing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICON-7 and GOG-218 Bevacizumab Regimens for Advanced Ovarian Cancer

Both ICON-7 and GOG-218 are bevacizumab-containing regimens combined with carboplatin and paclitaxel chemotherapy for advanced ovarian cancer, but they differ critically in bevacizumab dosing (7.5 mg/kg vs 15 mg/kg) and treatment duration (12 vs 15 months). These regimens represent the two validated approaches for incorporating bevacizumab into first-line ovarian cancer treatment, though neither is universally recommended due to modest benefits and quality-of-life concerns 1, 2, 3.

ICON-7 Regimen

The ICON-7 protocol uses lower-dose bevacizumab over a shorter duration 1, 2, 3, 4:

  • Paclitaxel 175 mg/m² IV over 3 hours + Carboplatin AUC 5-6 IV + Bevacizumab 7.5 mg/kg IV on Day 1
  • Repeat every 3 weeks for 5-6 cycles (concurrent phase)
  • Continue bevacizumab 7.5 mg/kg alone every 3 weeks for up to 12 additional cycles (maintenance phase)
  • Total treatment duration: approximately 12 months (18 cycles total)

ICON-7 Patient Population and Outcomes

ICON-7 enrolled a broader population including high-risk early-stage disease (FIGO stage I-IIa with grade 3 or clear cell histology) and advanced disease (stage IIb-IV), not just those with macroscopic residual disease 4. The trial showed improved progression-free survival but no overall survival benefit in the general population 5. However, a predefined high-risk subgroup (stage III with >1 cm residual disease or stage IV) demonstrated both PFS and OS improvement 4.

GOG-218 Regimen

The GOG-218 protocol uses higher-dose bevacizumab over longer duration 1, 2, 3, 1:

  • Paclitaxel 175 mg/m² IV over 3 hours + Carboplatin AUC 6 IV on Day 1 for 6 cycles (every 3 weeks)
  • Starting Day 1 of cycle 2: add Bevacizumab 15 mg/kg IV every 3 weeks
  • Continue bevacizumab 15 mg/kg alone every 3 weeks for up to 22 total cycles (maintenance phase)
  • Total treatment duration: approximately 15 months

GOG-218 Patient Population and Outcomes

GOG-218 enrolled only patients with stage III-IV disease with macroscopic residual disease after surgery 4. The trial demonstrated improved PFS (median 14.1 vs 10.3 months) but no overall survival benefit 1, 6. Notably, bevacizumab was not given during cycle 1 of chemotherapy in GOG-218, distinguishing it from ICON-7 1.

Critical Differences Between Regimens

Parameter ICON-7 GOG-218
Bevacizumab dose 7.5 mg/kg 15 mg/kg
Bevacizumab start Cycle 1, Day 1 Cycle 2, Day 1
Total duration ~12 months (18 cycles) ~15 months (22 cycles)
Carboplatin AUC 5-6 6
Patient population Broader (includes high-risk early stage) Restricted (stage III-IV with residual disease)

Clinical Application and Caveats

The NCCN guidelines list both regimens as Category 2B or Category 3 recommendations, reflecting significant panel disagreement about routine bevacizumab use in first-line ovarian cancer 1, 3, 1. The controversy stems from:

  • No overall survival benefit in unselected populations 1, 5
  • Quality-of-life decrements during maintenance therapy 7: ICON-7 showed a 6.4-point lower global QoL score at week 54 with bevacizumab (p<0.0001), which is clinically significant
  • Serious toxicity risks: 2-3% risk of gastrointestinal perforation/fistula 1
  • High cost without clear survival advantage 1

When to Consider These Regimens

Bevacizumab should be prioritized for high-risk patients with poor prognostic features 4:

  • Stage IV disease
  • Stage III with suboptimal debulking (>1 cm residual disease)
  • Poor tumor chemosensitivity (unfavorable KELIM score <1.0) 8

In the ICON-7 high-risk subgroup, bevacizumab improved OS (restricted mean survival 39.3 vs 34.5 months, p=0.03) 5. Similarly, GOG-218 validation studies showed greatest benefit in patients with high-risk disease and unfavorable chemosensitivity (PFS HR 0.64, OS HR 0.79) 8.

Important Safety Considerations

Bevacizumab must be withheld for 6 weeks before interval debulking surgery to allow adequate wound healing 2. This is particularly critical in the neoadjuvant setting, where bevacizumab use remains controversial and increases gastrointestinal perforation risk 9, 10.

The European Medicines Agency licensed bevacizumab at 15 mg/kg (GOG-218 dose), not the 7.5 mg/kg ICON-7 dose 4, though both regimens remain in clinical use depending on institutional preference and patient risk stratification.

References

Guideline

ovarian cancer, version 3.2012.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Guideline

nccn guidelines insights: ovarian cancer, version 1.2019.

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

Guideline

ovarian cancer, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Guideline

epithelial ovarian cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

Related Questions

What are the approved cancer indications for bevacizumab (Avastin), the recommended dosing schedules for each indication, the contraindications, and the monitoring and management recommendations?
What is the evidence base for bevacizumab (Avastin) in epithelial ovarian, primary peritoneal, and fallopian‑tube cancer, including details of all clinical trials, their results, and subgroup analyses?
In recurrent ovarian cancer, is VEGF molecular testing required before initiating bevacizumab therapy?
In an adult cancer patient receiving bevacizumab (Avastin), should the drug be held before a pleural tap (thoracentesis), and what is the recommended timing to discontinue and restart it?
How many cycles of bevacizumab should be administered in the ICON7 and GOG‑218 trials?
Is it not critical to miss a single dose of apixaban?
What is the stepwise ladder approach for pain management in the emergency department, and in which clinical situations are steroids or selective serotonin reuptake inhibitors indicated rather than relying solely on opioids and nonsteroidal anti‑inflammatory drugs?
In a newborn whose mother had equivocal antenatal herpes simplex virus (HSV) IgM serology but no active lesions, and the infant is clinically well while HSV serology is pending, what is the appropriate management?
Is a serum creatinine of 0.54 mg/dL measured over the past eight months within the normal range and indicative of preserved renal function?
Which medications can be used to treat sarcopenia in adults?
What platelet count threshold warrants withholding aspirin, clopidogrel (Plavix), and anticoagulants prior to an invasive procedure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.